Tprg1l, also known as Mover, is a protein-coding gene with diverse functions. It is involved in multiple biological processes, such as regulating the probability of neurotransmitter release in neurons [5,6,7]. It is also associated with lipid droplets in astrocytes, potentially playing a role in lipid-related neurological disorders [2]. Additionally, Tprg1l can upregulate IL-6 expression via NF-κB stimulation, indicating its role in inflammatory-related pathways [3].

In gallbladder cancer, tRF-3013b can inhibit cancer cell proliferation by targeting Tprg1l and repressing NF-κB. Overexpression of Tprg1l could rescue the inhibitory effects of tRF-3013b on gallbladder cancer cell proliferation, suggesting its importance in cancer-related biological processes [1]. In human cytomegalovirus infection, mutants lacking parts of the RNA1.2 gene upregulate Tprg1l, which in turn activates NF-κB and increases the extracellular release of IL-6 [3]. TERC, the RNA component of telomerase, can enhance the expression of Tprg1l, stimulating the NK-κB pathway and the expression and secretion of inflammatory cytokines [4].

In conclusion, Tprg1l is a gene with important functions in multiple biological processes. Its role in regulating neurotransmitter release, lipid droplet regulation in astrocytes, and involvement in NF-κB-related inflammatory pathways has been demonstrated. In diseases like gallbladder cancer and during viral infections, Tprg1l plays a significant role in disease-associated biological mechanisms, highlighting its potential as a therapeutic target.